{
    "additionDate": "2020-01-14T09:11:53Z",
    "bioagentsCURIE": "bioagents:NeoFuse",
    "bioagentsID": "NeoFuse",
    "confidence_flag": "agent",
    "description": "Predicting fusion neoantigens from RNA sequencing data.\n\nThe Section for Bioinformatrics at the Biocenter of Innsbruck Medical University is commited to the generation, management, integration, and leveraging data from genomics studies.\n\nQuantification of the tumor immune contexture.\n\nZlatko Trajanoski awarded with ERC Advanced Grant.",
    "editPermission": {
        "type": "public"
    },
    "function": [
        {
            "operation": [
                {
                    "term": "Peptide immunogenicity prediction",
                    "uri": "http://edamontology.org/operation_0252"
                },
                {
                    "term": "Quantification",
                    "uri": "http://edamontology.org/operation_3799"
                },
                {
                    "term": "Sequence assembly",
                    "uri": "http://edamontology.org/operation_0310"
                }
            ]
        }
    ],
    "homepage": "https://icbi.i-med.ac.at/NeoFuse/",
    "lastUpdate": "2021-01-04T07:49:53Z",
    "license": "GPL-3.0",
    "name": "NeoFuse",
    "owner": "Pub2Agents",
    "publication": [
        {
            "doi": "10.1093/BIOINFORMATICS/BTZ879",
            "metadata": {
                "abstract": "Â© 2019 The Author(s). Published by Oxford University Press.Summary: Gene fusions can generate immunogenic neoantigens that mediate anticancer immune responses. However, their computational prediction from RNA sequencing (RNA-seq) data requires deep bioinformatics expertise to assembly a computational workflow covering the prediction of: fusion transcripts, their translated proteins and peptides, Human Leukocyte Antigen (HLA) types, and peptide-HLA binding affinity. Here, we present NeoFuse, a computational pipeline for the prediction of fusion neoantigens from tumor RNA-seq data. NeoFuse can be applied to cancer patients' RNA-seq data to identify fusion neoantigens that might expand the repertoire of suitable targets for immunotherapy.",
                "authors": [
                    {
                        "name": "Finotello F."
                    },
                    {
                        "name": "Fotakis G."
                    },
                    {
                        "name": "Haider M."
                    },
                    {
                        "name": "Rieder D."
                    },
                    {
                        "name": "Trajanoski Z."
                    }
                ],
                "citationCount": 3,
                "date": "2020-04-01T00:00:00Z",
                "journal": "Bioinformatics",
                "title": "NeoFuse: Predicting fusion neoantigens from RNA sequencing data"
            },
            "pmid": "31755900"
        }
    ],
    "agentType": [
        "Desktop application"
    ],
    "topic": [
        {
            "term": "Gene transcripts",
            "uri": "http://edamontology.org/topic_3512"
        },
        {
            "term": "Immunoproteins and antigens",
            "uri": "http://edamontology.org/topic_2830"
        },
        {
            "term": "Oncology",
            "uri": "http://edamontology.org/topic_2640"
        },
        {
            "term": "RNA-Seq",
            "uri": "http://edamontology.org/topic_3170"
        },
        {
            "term": "Small molecules",
            "uri": "http://edamontology.org/topic_0154"
        }
    ],
    "validated": 1
}
